Stay updated with breaking news from N4 Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
X4 Pharmaceuticals (XFOR), focused on rare diseases of the immune system, announced Monday that the U.S. Food and Drug Administration or FDA has approved XOLREMDI (mavorixafor) capsules for use in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis).
N4 Pharma Plc (LON:N4P – Get Free Report)’s share price reached a new 52-week low on Monday . The stock traded as low as GBX 0.70 ($0.01) and last traded at GBX 0.70 ($0.01), with a volume of 177605 shares. The stock had previously closed at GBX 0.78 ($0.01). N4 Pharma Stock Down 9.7 % […]
Shares of N4 Pharma Plc (LON:N4P – Get Free Report) hit a new 52-week low on Monday . The company traded as low as GBX 0.70 ($0.01) and last traded at GBX 0.70 ($0.01), with a volume of 177605 shares trading hands. The stock had previously closed at GBX 0.78 ($0.01). N4 Pharma Stock Performance […]
RNS Announcements relating to N4 Pharma . All announcements from sources including RNS,PRN,BZW,NLK,CCN,CIS,HUG,AFX,TNS
N4 Pharma Plc (LON:N4P – Get Free Report) fell 9.4% on Thursday . The stock traded as low as GBX 1.40 ($0.02) and last traded at GBX 1.45 ($0.02). 1,483,516 shares traded hands during trading, an increase of 150% from the average session volume of 593,021 shares. The stock had previously closed at GBX 1.60 […]